Hadassah

Hadassah-Pluristem Trial Approved for Placental Cell Bone Marrow Regeneration

Monday, Feb 22 2016

The Federal Drug Administration (FDA) has approved the start of a Phase I trial with a placental-cell based therapy to mitigate acute radiation syndrome (ARS) and enhance bone marrow regeneration following a bone marrow transplant. The product, PLX-R18, was developed by Pluristem Therapeutics based on studies of Prof. Raphael Gorodetsky, head of Hadassah’s Biotechnology and Radiobiology Laboratories at the Sharett Institute of Oncology.

ARS (sometimes known as radiation toxicity or radiation sickness) is an acute lethal illness caused by irradiation of the entire body (or most of the body) by a high dose of penetrating radiation in a very short period of time. The syndrome affects the body’s ability to form new blood cells (hematopoietic recovery).

Prof. Gorodetsky and his colleagues helped Pluristem to identify the potency of the new cell product, having conducted an extensive preclinical study at Hadassah. The preclinical findings with PLX-R18 cells (also termed PLX-RAD) were initially published in PLOS-ONE (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0066549) by Prof. Raphael Gorodetsky and the development team, and they were further verified at the National Institutes of Health (NIH) and other prominent centers in the United States. The new cell product’s mechanism of action was also explored in collaboration with the Charité Univeristy Medical Center in Berlin, where its researchers revealed that PLX-R18 cells secrete a wide range of specific proteins which could trigger the resurgence of the necessary early descendants of stem cells (progenitor cells) that can differentiate to form one or more kinds of cell and support the regeneration of all blood cell lineages.

The preclinical studies paved the way for PLX-R18’s application as a new treatment for cancer patients who suffer complications following high-dose radiation and chemotherapy. “PLX-R18-based therapy,” notes Prof. Gorodetsky, “may present a breakthrough in the lifesaving treatment of acute radiation syndrome, which so far has had very limited alternative treatments. It can be anticipated that this cell therapy may serve also as a safe and easy treatment for a variety of severe hematopoietic disorders.”

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, May 23 2017

First Ladies Melania Trump and Sara Netanyahu Visit Hadassah Hospital

Please share our pride in Hadassah Hospital, singled out by the Israeli government to showcase the nation’s top-quality medicine, top doctors, and innovative medical research. First Lady Melania Trump and First Lady Sara Netanyahu visited Hadassah Hospital Ein Kerem on May 22...

READ MORE ›
alt_text

Wednesday, May 10 2017

Hadassah’s Melanoma Maven Featured in Hadassah Magazine

Metastatic melanoma is typically fatal, but Hadassah Hospital’s Prof. Michal Lotem, a world-renowned, cutting-edge physician/scientist, is trailblazing new treatments that are being watched around the globe.

READ MORE ›
alt_text

Monday, May 1 2017

Hadassah Surgeon to Light Torch at Jerusalem Independence Day Ceremony

Meet Prof. Ahmed Eid of Hadassah Hospital, who will light the torch at Jerusalem's Independence Day Ceremony, in honor of the city’s doctors who tirelessly work to save lives and improve the quality of life of men, women and children.

READ MORE ›

Friday, Apr 28 2017

Surgeons Perform World’s First-Ever Dual Robotic Surgery
 at Jerusalem’s Hadassah Hospital

The world’s first-of-its-kind dual robotic surgery was performed on April 23 at Hadassah Hospital Ein Kerem in Jerusalem, announced National President Ellen Hershkin of Hadassah, the Women’s Zionist Organization of America, Inc. (HWZOA).

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More